Collection |

Artificial intelligence in drug development

From rapid candidate selection, to fewer clinical trials and faster market approval, artificial intelligence approaches are helping to accelerate and improve the efficiency of drug development, whilst significantly reducing costs. Here we present a number of companies working in the field.

Feature content

Profiles

Auransa’s AI-driven prediction of drug candidates and corresponding patient responders increases the chances of clinical trial success.

Advertisement Feature |

Chemiverse provides a quicker route to ‘the best target, the best chemical,’ according to the Korean biotech Pharos iBio. With its first AI-based drug currently undergoing clinical trials, the company is demonstrating the broad value AI can provide from discovery to clinical development.

Advertisement Feature |

Better data for better insights and improved outcomes—Molecular Health has built one of the largest, deepest and fully curated digital platforms for biomedicine in the world. The company’s ‘Dataome’ provides the foundation for actionable insights for stakeholders across the healthcare ecosystem.

Advertisement Feature |

Deep Quartet, a drug discovery platform developed by INTAGE Healthcare and the Institute for Theoretical Medicine (ITM) uses AI technologies to design new lead compound structures based on pharmacophore models.

Advertisement Feature |

Paige, a global leader in artificial intelligence–based diagnostic software, has built a flexible and scalable digital pathology platform that streamlines tissue analysis and affords opportunities for novel biomarker discovery. The company has a flexible partnership model designed to maximize outcomes for collaborators and patients.

Advertisement Feature |